SCHEMBL3266280

SCHEMBL3266280

CC(C)N(C(C)C)P(O)OC(Cl)CC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7457089 0.83
SCHEMBL5057324 0.81
SCHEMBL2953096 0.80
SCHEMBL992012 0.76
SCHEMBL963229 0.72 TSHR (0.31)
SCHEMBL26187546 0.69
SCHEMBL1061098 0.68
SCHEMBL252367 0.67 TSHR (0.30)
SCHEMBL7858703 0.67 TSHR (0.30)
SCHEMBL7262903 0.67 TSHR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048436-A1 Methods of synthesizing chemically cleavable phosphoramidite linkers NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-19 US claimed
EP-3362089-B1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS SANOFI PASTEUR (FR) 2023-12-06 EP disclosed
EP-3296306-B1 BASE-PROTECTED OLIGONUCLEOTIDE AJINOMOTO KK (JP) 2022-11-09 EP disclosed
EP-2816053-B1 BASE-PROTECTED OLIGONUCLEOTIDE AJINOMOTO KK (JP) 2021-03-24 EP disclosed
US-10772946-B2 Immunogenic compositions against S. aureus SANOFI PASTEUR (FR) 2020-09-15 US disclosed
US-20180280491-A1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS SANOFI PASTEUR (FR) 2018-10-04 US disclosed
EP-3296306-A1 BASE-PROTECTED OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2018-03-21 EP disclosed
EP-2976351-B1 LIPOHILLIC OLIGONUCLEOTIDE ANALOGS MILTENYI BIOTEC GMBH (DE) 2018-02-21 EP disclosed
US-9803198-B2 Lipohillic oligonucleotide analogs MILTENYI BIOTEC, GMBH (DE) 2017-10-31 US disclosed
US-9371353-B2 Oligonucleotide with protected base AJINOMOTO CO., INC. (JP) 2016-06-21 US disclosed
US-20130267697-A1 OLIGONUCLEOTIDE WITH PROTECTED BASE AJINOMOTO CO., INC. (JP) 2013-10-10 US disclosed
EP-2144633-A2 A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI Segev Laboratories Limited (IL) 2010-01-20 EP disclosed
US-20090048436-A1 Methods of synthesizing chemically cleavable phosphoramidite linkers NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-19 US disclosed
US-20090047712-A1 Chemically cleavable phosphoramidite linkers NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-19 US disclosed
WO-2008129548-A2 A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SEGEV LABORATORIES LIMITED (IL) 2008-10-30 WO disclosed
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2008-01-03 US disclosed
US-20060160763-A1 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2006-07-20 US disclosed
WO-2006010084-A2 A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI SEGEV LABORATORIES LIMITED (IL) 2006-01-26 WO disclosed
EP-0691979-A1 NOVEL 5'-SUBSTITUTED NUCLEOSIDES AND OLIGOMERS PRODUCED THEREFROM SANOFI (FR) 1996-01-17 EP disclosed
WO-1994022890-A1 NOVEL 5'-SUBSTITUTED NUCLEOSIDES AND OLIGOMERS PRODUCED THEREFROM STERLING WINTHOP INC. (US) 1994-10-13 WO disclosed